The board of directors of Fortis Healthcare Limited is scheduled to meet on Friday, February 13, 2026 to consider and approve Q3 results. According to the company's announcement in an exchange filing, the board meeting will be held to inter-alia, consider and approve the Un-audited Financial Results (Standalone and Consolidated) of the company for the quarter and period ended December 31, 2025. The company has also declared that the trading window will remain closed until 48 hours after the announcement of the financial results, up to February 15, 2026.
The upcoming board meeting will focus on the company's Q3 FY26 financial results, covering both standalone and consolidated financial statements. As reported by the company in its exchange filing, the meeting will specifically address the quarter and period ended December 31, 2025, indicating the results will cover the third quarter of the current financial year. The results pertain to the quarter that concluded on December 31, 2025 (Q3).
In addition to the board meeting announcement, Fortis Healthcare has informed that the trading window, which restricts trading in the company's securities, will remain closed until 48 hours following the official announcement of the financial results. Specifically, the trading window will be lifted after February 15, 2026. This closure ensures proper regulatory compliance and prevents insider trading during the sensitive period of results announcement.
The announcement was made through an exchange filing, ensuring proper regulatory disclosure requirements are met. According to the company's official statement, the board meeting will be held to consider and approve the financial results, following standard corporate governance procedures for quarterly reporting. The company has maintained transparency by providing clear timelines for both the board meeting and trading window reopening.
